Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics

Glioblastoma (GB) is the most common and aggressive primary brain malignancy, with poor prognosis and a lack of effective therapeutic options. Accumulating evidence suggests that intratumor heterogeneity likely is the key to understanding treatment failure. However, the extent of intratumor heterogeneity as a result of tumor evolution is still poorly understood. To address this, we developed a unique surgical multisampling scheme to collect spatially distinct tumor fragments from 11 GB patients. We present an integrated genomic analysis that uncovers extensive intratumor heterogeneity, with most patients displaying different GB subtypes within the same tumor. Moreover, we reconstructed the phylogeny of the fragments for each patient, identifying copy number alterations in EGFR and CDKN2A/B/p14ARF as early events, and aberrations in PDGFRA and PTEN as later events during cancer progression. We also characterized the clonal organization of each tumor fragment at the single-molecule level, detecting multiple coexisting cell lineages. Our results reveal the genome-wide architecture of intratumor variability in GB across multiple spatial scales and patient-specific patterns of cancer evolution, with consequences for treatment design.

[1]  A. Álvarez-Buylla,et al.  Neurogenesis in the Adult Brain I , 2011 .

[2]  Zhongming Zhao,et al.  Uncovering MicroRNA and Transcription Factor Mediated Regulatory Networks in Glioblastoma , 2012, PLoS Comput. Biol..

[3]  T. Sano,et al.  Loss of chromosome 10 in glioblastoma: Relation to proliferation and angiogenesis , 1999, Pathology international.

[4]  K. Aldape,et al.  The Use of Global Profiling in Biomarker Development for Gliomas , 2011, Brain pathology.

[5]  P. Diegelman,et al.  Methylthioadenosine phosphorylase, a gene frequently codeleted with p16(cdkN2a/ARF), acts as a tumor suppressor in a breast cancer cell line. , 2002, Cancer research.

[6]  K. Polyak,et al.  Tumor heterogeneity: causes and consequences. , 2010, Biochimica et biophysica acta.

[7]  S. Tavaré,et al.  Investigating stem cells in human colon by using methylation patterns , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[8]  S. Gabriel,et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. , 2010, Cancer cell.

[9]  Simon Tavaré,et al.  Integrating Approximate Bayesian Computation with Complex Agent-Based Models for Cancer Research , 2010, COMPSTAT.

[10]  E. Lander,et al.  Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma , 2007, Proceedings of the National Academy of Sciences.

[11]  A. Børresen-Dale,et al.  The Life History of 21 Breast Cancers , 2012, Cell.

[12]  Francisco Tirado,et al.  GeneCodis: interpreting gene lists through enrichment analysis and integration of diverse biological information , 2009, Nucleic Acids Res..

[13]  J. Griffiths,et al.  Fluorescence-guided surgical sampling of glioblastoma identifies phenotypically distinct tumour-initiating cell populations in the tumour mass and margin , 2012, British Journal of Cancer.

[14]  Bernardo Celda,et al.  New pattern of EGFR amplification in glioblastoma and the relationship of gene copy number with gene expression profile , 2010, Modern Pathology.

[15]  K. Polyak,et al.  Intra-tumour heterogeneity: a looking glass for cancer? , 2012, Nature Reviews Cancer.

[16]  Kenric Leung,et al.  The Life History of 21 Breast Cancers , 2015, Cell.

[17]  C. Maley,et al.  Cancer is a disease of clonal evolution within the body1–3. This has profound clinical implications for neoplastic progression, cancer prevention and cancer therapy. Although the idea of cancer as an evolutionary problem , 2006 .

[18]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[19]  F. Cleton Evolution of Cancer , 1991, British Journal of Cancer.

[20]  J. Troge,et al.  Inferring tumor progression from genomic heterogeneity. , 2010, Genome research.

[21]  F. Zanella,et al.  Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. , 2006, The Lancet. Oncology.

[22]  S. McWeeney,et al.  Cancer stem cell tumor model reveals invasive morphology and increased phenotypical heterogeneity. , 2010, Cancer research.

[23]  D P Byar,et al.  Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. , 1980, The New England journal of medicine.

[24]  Charles Swanton,et al.  Intratumor Heterogeneity: Seeing the Wood for the Trees , 2012, Science Translational Medicine.

[25]  M. Nowak,et al.  Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer , 2010, Nature.

[26]  Zhihui Xie,et al.  Nuclear Factor of Activated T Cells (NFAT) Proteins Repress Canonical Wnt Signaling via Its Interaction with Dishevelled (Dvl) Protein and Participate in Regulating Neural Progenitor Cell Proliferation and Differentiation* , 2011, The Journal of Biological Chemistry.

[27]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[28]  Andrea Sottoriva,et al.  Single-molecule genomic data delineate patient-specific tumor profiles and cancer stem cell organization. , 2013, Cancer research.

[29]  J. Salk Clonal evolution in cancer , 2010 .

[30]  Debyani Chakravarty,et al.  Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response , 2012, Proceedings of the National Academy of Sciences.

[31]  E. Letouzé,et al.  Analysis of the copy number profiles of several tumor samples from the same patient reveals the successive steps in tumorigenesis , 2010, Genome Biology.

[32]  Simon Tavaré,et al.  The Stem Cell Population of the Human Colon Crypt: Analysis via Methylation Patterns , 2007, PLoS Comput. Biol..

[33]  Peter J. Campbell,et al.  Evolution of the cancer genome , 2012, Nature Reviews Genetics.

[34]  Simon Tavaré,et al.  Modeling Evolutionary Dynamics of Epigenetic Mutations in Hierarchically Organized Tumors , 2011, PLoS Comput. Biol..

[35]  N G Burnet,et al.  Years of life lost (YLL) from cancer is an important measure of population burden – and should be considered when allocating research funds , 2005, British Journal of Cancer.

[36]  J. Uhm Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2009 .

[37]  R. Gillies,et al.  Evolutionary dynamics of carcinogenesis and why targeted therapy does not work , 2012, Nature Reviews Cancer.

[38]  Rebecca A Betensky,et al.  Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. , 2011, Cancer cell.

[39]  Satoshi Ota,et al.  NLK positively regulates Wnt/β‐catenin signalling by phosphorylating LEF1 in neural progenitor cells , 2012, The EMBO journal.

[40]  V P Collins,et al.  Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. , 1996, Oncogene.

[41]  Martin J. van den Bent,et al.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.

[42]  C. Perou,et al.  Allele-specific copy number analysis of tumors , 2010, Proceedings of the National Academy of Sciences.

[43]  A. Levine,et al.  The Control of the Metabolic Switch in Cancers by Oncogenes and Tumor Suppressor Genes , 2010, Science.

[44]  Paul Marjoram,et al.  Inferring clonal expansion and cancer stem cell dynamics from DNA methylation patterns in colorectal cancers , 2009, Proceedings of the National Academy of Sciences.

[45]  Thomas D. Wu,et al.  Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. , 2006, Cancer cell.